top of page


CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe
The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.

nuaxia
1 day ago2 min read


UK MHRA approves Incyte's Zynyz for advanced anal cancer as NICE backs NHS access
The UK MHRA has authorised Incyte's Zynyz with carboplatin and paclitaxel for advanced anal cancer, accompanied by a positive NICE access recommendation and Phase III evidence of improved median overall survival.

nuaxia
4 days ago2 min read


FDA grants accelerated approval to Inovio Voceryq as first US plasmid DNA-based immunotherapy
The FDA has granted accelerated approval to Inovio's Voceryq, marking the first US authorisation of a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.

nuaxia
Nov 22 min read


FDA grants full approval to Keytruda and Keytruda Qlex for TMB-high advanced solid tumours with updated biomarker threshold
The FDA has converted Keytruda's tumour-mutational-burden-high solid tumour indication to traditional approval, extending the authorisation to Keytruda Qlex and updating the biomarker threshold.

nuaxia
Oct 232 min read


FDA grants accelerated approval to GSK Jemperli for MSI-H or dMMR locally advanced rectal cancer
The FDA has granted accelerated approval to GSK's Jemperli for previously untreated MSI-H or dMMR locally advanced rectal cancer, introducing a potentially organ-preserving immunotherapy approach.

nuaxia
Oct 202 min read


FDA expands Anktiva approval to high-grade papillary-only BCG-unresponsive bladder cancer
The FDA has expanded Anktiva's approval to include adults with high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer, establishing the first approved treatment specifically for this population.

nuaxia
Oct 152 min read


FDA approves Roche Tecentriq combination as first adjuvant immunotherapy for stage III dMMR colon cancer
The FDA has approved Roche's Tecentriq-based chemotherapy regimen as the first adjuvant immunotherapy option for eligible patients with stage III mismatch repair-deficient colon cancer.

nuaxia
Oct 142 min read


Valerio Therapeutics agrees €30 million Etherna acquisition alongside €40.25 million financing
The transaction combines Valerio’s targeted delivery technologies with Etherna’s mRNA, lipid nanoparticle and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.

nuaxia
Aug 263 min read


HanchorBio partners with Taiwan Cancer Moonshot team to advance precision immunotherapy development
The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.

nuaxia
Aug 132 min read


FDA grants accelerated approval to Tudriqev for PD-1-refractory advanced melanoma
The engineered oncolytic viral therapy, used with nivolumab, provides a new treatment option for adults with unresectable cutaneous melanoma that has progressed despite prior PD-1-based immunotherapy.

nuaxia
Aug 72 min read
bottom of page